Theralase Technologies Inc. Receives Canadian Patent for Cancer Vaccine

Theralase® Technologies Inc., a Toronto-based clinical stage pharmaceutical company, has secured a Canadian patent for its innovative cancer vaccine. This patent centers around the use of Photo Dynamic Compounds (PDCs) to inactivate cancer cells via photodynamic treatment, linked with immunotherapy.

This development follows a US patent awarded in October 2022 and precedes a pending patent in the European Union. The technology enables the extraction, treatment, and re-introduction of cancer cells into patients, aiming to train their immune systems to combat the cancer effectively.

Theralase®'s ongoing projects include a Phase II study for bladder cancer and upcoming Phase Ib studies for brain and lung cancers, with the latest patents promising expansion into treatments for "liquid cancers" such as leukemia, lymphoma, and myeloma.

Dr. Arkady Mandel and Roger DuMoulin-White highlight the patent's significance, viewing it as a significant stride in broadening treatment potentials for various cancers, with a focus now extending towards blood-related cancers.

Theralase® is prioritizing the pursuit of additional financing to advance its clinical studies, aimed at both solid-core and liquid cancers, leveraging its patented PDC technology to significantly enhance cancer treatment options.